7th ICHNO Abstract book

page 32 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ 7th ICHNO

status was not available in time frame. Table 1 shows baseline characteristics Only 25% of patients managing to complete the expected 7-8 cycles (depending on RT schedule) of cetuximab. The main reasons for discontinuing were skin toxicity and/or mucositis. 95% completed radiotherapy as planned, with 4/83 stopping early (2 patient choice, 1 died unexpectedly on treatment, 1 switched to palliation). G3 or greater dysphagia on completion of RT was 63% (45/71) in the whole group and by 6 months this had fallen to 20% (13/64). At 2 years this was 13% (6/43) but only 6% (2/33) if considering just those who were disease free. OS of whole group at two years was 57/83 (68%) with median OS 48.9 months (95% CI 34.5 to 67.8 months). Locoregional control at two years was 51/72 (70%). Completing more than 6 or more cycles cetuximab in this group increased survival probability compared to less than 6 (Table 2) this was statistically significant (log rank of equality of survival functions p=0.046).

hemoglobin and serum albumin, before definitive radiation for head and neck squamous cell carcinoma (HNSCC) predict survival and locoregional control. Material and Methods Retrospective study included patients with pathologically proven HNSCC undergoing definitive RT at a single tertiary level referral university cancer center, Alexandria Clinical Oncology Department (ACOD), during the period from January 1, 2005 to December 31, 2015. The effect of pre- RT BMI, serum hemoglobin and serum albumin on survival and disease control were evaluated. Results 215 patients met our inclusion criteria. Of these, 31 (14.4%) were women and 184 (85.6%) were men. Their mean age was 57.21 (+/- 9.7). Laryngeal SCC constituted most of cases with 84 (39.06%) patients followed by oropharyngeal SCC with 69 (32.1%) patients. In multivariate analysis, BMI (25) and hemoglobin (<=12g/dl vs >12g/dl for females and 14g/dl for males) pre-RT correlated significantly with both survival ((HR, .409; 95%CI, 0.254-0.659; P = <.0001) for BMI and (HR, .367; 95%CI,0.211-0.639; P = <.0001) for hemoglobin) and locoregional control ((HR, .431; 95%CI, 0.246-0.755; P = .003) for BMI and (HR, 2.554; 95%CI,1.328-4.911; P = .005) for hemoglobin). In contrast, Serum albumin showed insignificant correlation, both when taken as a continuous variable and when taken as a categorical variable (<3.5mg/dl vs =/>3.5mg/dl), with both survival (HR,1.035;95%CI,.429-2.498; P = .939) and locoregional control(HR,1.688;95%CI,.655-4.351; P =.279). Conclusion BMI and serum hemoglobin pre-treatment can predict oncologic outcomes for patients with HNSCC, whereas pre- treatment serum albumin does not predict locoregional control nor survival. Our study can be the basis to use easy-to-obtain parameters like BMI and serum hemoglobin to stratify HNSCC patients who are in need for more in- depth nutritional assessment and interventions pre-RT with hope of reflection on treatment outcome. PO-060 Outcomes from concomitant cetuximab with radiotherapy in HNSCC: A retrospective cohort study C. Paterson 1 , A. Morton 1 , C. Lamb 1 , C. Wilson 1 , D. Grose 1 , M. Rizwanullah 1 , S. Schipani 1 , F. Easton 2 , F. Campbell 2 , A. James 1 , M. Philip 1 , M. Thomson 3 1 Beatson WoSCC, Clinical Oncology, Glasgow, United Kingdom ; 2 Beatson WoSCC, Head & Neck Nurse Specialist, Glasgow, United Kingdom ; 3 Beatson WoSCC, Therapeutic Radiography, Glasgow, United Kingdom Purpose or Objective For patients with locally advanced HNSCC chemoRT is standard of care for non-surgical treatment. Concurrent cisplatin is the preferred agent but cetuximab also improves disease control compared to RT alone and is used in patients with contraindications to cisplatin. The aim of this work was to evaluate outcomes of patients treated with cetuximab-RT. Material and Methods Patients prescribed cetuximab-RT were identified from electronic prescribing system. Electronic case records were reviewed for the 83 patients identified. Results Patient demographics are typical for a UK locally advanced HNSCC practice, 75% male, mean age 62 years. Multiple primary sites and stages were included. Stage IV-A oropharynx represented the largest subgroup (n=27), HPV

Conclusion Only 25% of patients completed planned cetuximab, considerably less than 90% achieved in the pivotal study and 48.9% in retrospective French data. Despite this RT delivery was not compromised. Survival probability was better in patients who were able to tolerate 6+ cycles of cetuximab. OS at two years is as anticipated for this cohort of locally advanced HNSCC and similar to the Bonner study. Acute toxicity is similar to that expected with Cisplatin-RT although late dysphagia of 6% at two years compares favourably.